Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m&lt;sup&gt;7&lt;/sup&gt;G modification. The gene discussed is NET1; the disease is non-small cell lung carcinoma.